These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 525647)

  • 21. [Studies of biological availability. A critical assessment based on a study of spironolactone preparations].
    Rameis H; Bacher S
    Wien Med Wochenschr; 1988 Apr; 138(6-7):156-60. PubMed ID: 3394332
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bioavailability of pseudoephedrine and triprolidine from combination and single-ingredient products.
    Williams BO; Liao SH; Lai AA; Arnold JD; Perkins JG; Blum MR; Findlay JW
    Clin Pharm; 1984; 3(6):638-43. PubMed ID: 6509877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determination of canrenone, the major metabolite of spironolactone, in plasma and urine by high-performance liquid chromatography.
    Krause W; Karras J; Jakobs U
    J Chromatogr; 1983 Oct; 277():191-9. PubMed ID: 6643605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Drug treatment in the elderly: special aspects of diuretics (author's transl)].
    Mühlberg W; Platt D
    Aktuelle Gerontol; 1982 Jul; 12(4):134-8. PubMed ID: 6126136
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bioavailability of indomethacin tablets in men volunteers.
    Groth PE; Dunn JM
    Clin Pharm; 1986 Oct; 5(10):820-4. PubMed ID: 3780150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of metabolites--a new approach to bioequivalence studies of spironolactone formulations.
    Vergin H; Mahr G; Metz R; Eichinger A; Nitsche V; Martens H
    Int J Clin Pharmacol Ther; 1997 Aug; 35(8):334-40. PubMed ID: 9266289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of antacid on the bioavailabiity of lithium carbonate.
    Goode DL; Newton DW; Ueda CT; Wilson JE; Wulf BG; Kafonek D
    Clin Pharm; 1984; 3(3):284-7. PubMed ID: 6428800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Canrenone--the principal active metabolite of spironolactone?
    Ramsay LE; Shelton JR; Wilkinson D; Tidd MJ
    Br J Clin Pharmacol; 1976 Aug; 3(4):607-12. PubMed ID: 22216502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of micronization on the bioavailability and pharmacologic activity of spironolactone.
    McInnes GT; Asbury MJ; Ramsay LE; Shelton JR; Harrison IR
    J Clin Pharmacol; 1982; 22(8-9):410-7. PubMed ID: 7130430
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparative bioavailability of two forms of spironolactone. Rationalization applied to dosage (author's transl)].
    d'Athis P; Richard MO; de Lauture D; Rey E; Bouvier d'Yvoire M; Clement E; Olive G
    Therapie; 1981; 36(4):443-9. PubMed ID: 7292427
    [No Abstract]   [Full Text] [Related]  

  • 31. Spironolactone. I. Disposition and metabolism.
    Karim A; Zagarella J; Hribar J; Dooley M
    Clin Pharmacol Ther; 1976 Feb; 19(2):158-69. PubMed ID: 1261153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Absence of food effect on the extent of alprazolam absorption from an orally disintegrating tablet.
    Erdman K; Stypinski D; Combs M; Witt P; Stiles M; Pollock S
    Pharmacotherapy; 2007 Aug; 27(8):1120-4. PubMed ID: 17655512
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Villalpando-Hernández J; Novoa-Heckel G; Oliva I; Cariño L; López-Bojórquez E; Burke-Fraga V; Namur S; González-de la Parra M
    Clin Ther; 2009 Feb; 31(2):399-410. PubMed ID: 19302912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors influencing comparative bioavailability of spironolactone tablets.
    Clarke JM; Ramsay LE; Shelton JR; Tidd MJ; Murray S; Palmer RF
    J Pharm Sci; 1977 Oct; 66(10):1429-32. PubMed ID: 579186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spironolactone. III. Canrenone--maximum and minimum steady-state plasma levels.
    Karim A; Zagarella J; Hutsell TC; Dooley M
    Clin Pharmacol Ther; 1976 Feb; 19(2):177-82. PubMed ID: 1261155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of a simple fluorometric method on absorption of canrenone.
    Radó JP; Szende L; Takó J; Nagy O; Kozma C
    Int J Clin Pharmacol Biopharm; 1976 Mar; 13(2):123-6. PubMed ID: 1254376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects.
    Goren MP; Houle JM; Bush DA; Li JT; Newman CE; Brade WP
    Clin Cancer Res; 1998 Oct; 4(10):2313-20. PubMed ID: 9796960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
    Darwish M; Tempero K; Kirby M; Thompson J
    Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lack of endocrine systemic side effects after topical application of spironolactone in man.
    Rey FO; Valterio C; Locatelli L; Ramelet AA; Felber JP
    J Endocrinol Invest; 1988 Apr; 11(4):273-8. PubMed ID: 3411088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bioavailability of ergoloid mesylates liquid capsule.
    Schran HF
    Clin Ther; 1985; 8(1):71-5. PubMed ID: 3833371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.